-
Scandinavian Journal of Rheumatology 1990
Review
Topics: Adult; Arthritis, Rheumatoid; Azathioprine; Female; Humans; Urticaria
PubMed: 2186478
DOI: 10.3109/03009749009102122 -
Der Nervenarzt Apr 2007We present a 31-year-old female patient with primary non-Hodgkin's lymphoma of the CNS after immunosuppressive therapy. Colitis ulcerosa had been diagnosed 2 years... (Review)
Review
We present a 31-year-old female patient with primary non-Hodgkin's lymphoma of the CNS after immunosuppressive therapy. Colitis ulcerosa had been diagnosed 2 years previously. Prophylactic therapy with azathioprine over 9 months was stopped after the development of listeria meningitis which was treated successfully with antibiotics. At this time native CCT was normal. Three months later the patient developed an epileptic seizure and multiple cerebral lesions were detected in CCT and MRI. Although antibiotic therapy was started, the cerebral lesions showed no regression. Stereotactic biopsy revealed immunochemical and histologic high-grade malignant B cell lymphoma. The risk of primary CNS lymphoma under azathioprine treatment for an autoimmune disease with a possible congenital immunodeficiency is presented and the literature is reviewed.
Topics: Adult; Autoimmune Diseases; Azathioprine; Brain Neoplasms; Colitis, Ulcerative; Female; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin
PubMed: 17375274
DOI: 10.1007/s00115-007-2255-7 -
Gastroenterology Oct 2013A small placebo-controlled trial reported the efficacy of mercaptopurine therapy for children newly diagnosed with Crohn's disease, yet little is known about the... (Randomized Controlled Trial)
Randomized Controlled Trial
BACKGROUND & AIMS
A small placebo-controlled trial reported the efficacy of mercaptopurine therapy for children newly diagnosed with Crohn's disease, yet little is known about the efficacy of early thiopurine therapy in adults.
METHODS
We performed a prospective double-blind trial of adult patients with a recent (<8 weeks) diagnosis of Crohn's disease. Patients were randomly assigned to groups given azathioprine (2.5 mg · kg(-1) · day(-1), n = 68) or placebo (n = 63) at 31 hospitals from February 2006 to September 2009. Corticosteroids but no other concomitant medications were allowed for control of disease activity. The primary measure of efficacy was sustained corticosteroid-free remission.
RESULTS
After 76 weeks of treatment, 30 patients treated with azathioprine (44.1%) and 23 given placebo (36.5%) were in sustained corticosteroid-free remission (difference of 7.6%; 95% confidence interval, -9.2 to 24.4%; P = .48). The rates of relapse (defined as Crohn's Disease Activity Index score >175) and corticosteroid requirements were similar between groups. A post hoc analysis of relapse, defined as a Crohn's Disease Activity Index score >220, showed lower relapse rates in the azathioprine group than in the placebo group (11.8% vs 30.2%; P = .01). Serious adverse events occurred in 14 patients in the azathioprine group (20.6%) and 7 in the placebo group (11.1%) (P = .16). A larger percentage of patients in the azathioprine group had adverse events that led to study drug discontinuation (20.6%) than in the placebo group (6.35%) (P = .02).
CONCLUSIONS
In a study of adults with Crohn's disease, early azathioprine therapy was no more effective than placebo to achieve sustained corticosteroid-free remission but was more effective in preventing moderate to severe relapse in a post hoc analysis. EudraCT 2005-001186-34.
Topics: Adult; Azathioprine; Crohn Disease; Double-Blind Method; Female; Humans; Immunosuppressive Agents; Male; Prospective Studies
PubMed: 23770132
DOI: 10.1053/j.gastro.2013.06.009 -
Adverse Drug Reactions and... Dec 2000
Review
Topics: Animals; Azathioprine; Graft Rejection; Humans; Immunosuppressive Agents; Mercaptopurine; Polymorphism, Genetic; Treatment Outcome
PubMed: 11212460
DOI: No ID Found -
Medizinische Klinik (Munich, Germany :... Apr 2000An overview on the evidence-based indications for an immunosuppressive treatment with azathioprine in chronic inflammatory bowel diseases is given. CROHN'S DISEASE: In... (Review)
Review
AIM
An overview on the evidence-based indications for an immunosuppressive treatment with azathioprine in chronic inflammatory bowel diseases is given. CROHN'S DISEASE: In Crohn's disease, these are the induction of remission in chronic active Crohn's disease, steroid-dependent Crohn's disease, fistulizing Crohn's disease and the maintenance of remission in Crohn's disease. The optimal dose is 2.5 mg/kg body weight, treatment should be maintained for at least 4 years.
ULCERATIVE COLITIS
In ulcerative colitis, these are steroid dependency, the maintenance of remission in chronic active ulcerative colitis and the maintenance of remission after induction of remission with cyclosporin or tacrolimus in acute attacks of disease.
Topics: Azathioprine; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Evidence-Based Medicine; Humans; Immunosuppressive Agents
PubMed: 10808301
DOI: 10.1007/pl00002107 -
British Medical Journal Mar 1972
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Azathioprine; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic
PubMed: 5015288
DOI: 10.1136/bmj.1.5801.645 -
Lancet (London, England) Apr 1971
Topics: Azathioprine; Bile Ducts; Cholangiography; Cholangitis; Female; Humans; Middle Aged
PubMed: 4101317
DOI: 10.1016/s0140-6736(71)91261-x -
Die Medizinische Welt Jul 1976
Topics: Adult; Azathioprine; Cholestasis; Female; Granulomatosis with Polyangiitis; Hepatitis; Humans; Male
PubMed: 957953
DOI: No ID Found -
Lancet (London, England) Oct 1991The efficacy of azathioprine in the treatment of multiple sclerosis was assessed by meta-analysis of the results of all published blind, randomised, controlled trials.... (Meta-Analysis)
Meta-Analysis
The efficacy of azathioprine in the treatment of multiple sclerosis was assessed by meta-analysis of the results of all published blind, randomised, controlled trials. 793 patients were enrolled in 5 double-blind and 2 single-blind studies. After 1 year of treatment, the increase in Kurtzke disability status score was no different in treated and control groups, but at 2 years there was a small difference (-0.22; 95% confidence interval [CI] -0.43, 0.003) in favour of azathioprine treatment; this difference was sustained, but not increased, after 3 years. The probability of freedom from any relapse during 1, 2, and 3 years' treatment was significantly greater in the azathioprine-treated group (relative odds over 3 years 1.97; 95% Cl 1.27, 3.04), but it is debatable whether the slight clinical benefits of azathioprine outweigh its side-effects.
Topics: Azathioprine; Disability Evaluation; Follow-Up Studies; Humans; Meta-Analysis as Topic; Multiple Sclerosis; Probability; Randomized Controlled Trials as Topic; Recurrence
PubMed: 1681364
DOI: 10.1016/0140-6736(91)91909-e -
Journal of Neurology 1980The results of a prospective, long-term controlled study on the treatment of multiple sclerosis with azathioprine are reported. The effect of a daily 2 mg/kg body weight... (Clinical Trial)
Clinical Trial Randomized Controlled Trial
The results of a prospective, long-term controlled study on the treatment of multiple sclerosis with azathioprine are reported. The effect of a daily 2 mg/kg body weight dosage on 56 randomly chosen patients with multiple sclerosis is compared with a non-treated control group of 51 randomly selected multiple sclerosis patients. The azathioprine therapy was continued in all cases for more than one year, on average for 732 days. To assess the effect of therapy, the course of the disease was followed by regular examinations evaluating the severity of the disease by use of an objective weighting-scale covering the whole range of neurological signs. The individual course of the disease within the observation period was determined by means of regression analysis. On average, the disease deteriorated less rapidly for those undergoing azathioprine therapy, this being most marked for patients who had had the disease for less than two years. For those who had been affected for longer, no significant differences in the progression of the disease could be detected. The annual relapse rate was the same for both categories.
Topics: Adult; Azathioprine; Follow-Up Studies; Humans; Middle Aged; Multiple Sclerosis
PubMed: 6157007
DOI: 10.1007/BF00313173